MaxCyte, Inc. MaxCyte to Host Capital Markets Day Today (1593F)
July 11 2019 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 1593F
MaxCyte, Inc.
11 July 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte to Host Capital Markets Day Today
Gaithersburg, Maryland - 11 July 2019: MaxCyte (LSE: MXCT,
MXCS), the global cell-based therapies and life sciences company,
is today hosting a Capital Markets Day for institutional investors
and analysts in London.
Doug Doerfler, Chief Executive Officer, will host the event with
other members of Maxcyte's commercial, medical and financial
leadership team and leading key opinion leaders from the fields of
cell and gene therapy and immuno-oncology. The event will include
presentations on MaxCyte's Flow Electroporation(R) technology,
which underlies MaxCyte's 70+ partnered programme licenses, and the
differentiation of its CARMA(TM) platform, as well as a live
demonstration of its recently announced ExPERT(TM) family of
instruments.
The agenda follows:
-- Welcome and Introduction - Doug Doerfler, President & Chief Executive Officer
-- Customer Focus / Product and Applications Innovation - Brad
Calvin, EVP, Global Commercial Operations
-- Enabling Technologies: Role of Flow Electroporation - John
McCafferty, PhD, Founder and Chief Executive Officer, IONTAS
-- Immuno-Oncology Landscape and CARMA Differentiation -
Christina M. Annunziata, MD, PhD, Principal Investigator and
Clinical Director, National Cancer Institute
-- CARMA - the Clinical Pathway and Future Opportunities -
Claudio Dansky Ullmann, MD, Chief Medical Officer
-- Financial Overview - Ron Holtz, Chief Financial Officer
-- Closing and Questions - Doug Doerfler, President & Chief Executive Officer
Event details
The meeting will be held at the London Stock Exchange, 10
Paternoster Row, London, EC4M 7LS. The event will start at 15:00
BST, and will conclude with an informal drinks and networking
session from approximately 17:30 BST.
A video recording of all presentations will be available on the
MaxCyte website shortly after the event.
Please contact maxcyte@consilium-comms.com if you would like to
attend today's event and have not already registered.
No new price sensitive information will be disclosed on this
day. A trading update will be announced on 17 July 2019.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, with all of the top ten
global biopharmaceutical companies. The Company now has more than
70 partnered programme licenses in cell therapy with more than 35
licensed for clinical use, including four announced commercial
licenses covering potentially more than 30 products with aggregate
potential milestones of more than $250M. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFFIDEIILIA
(END) Dow Jones Newswires
July 11, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024